Header Logo

Connection

Rami Doukky to Pyrazoles

Back to Details
This is a "connection" page, showing publications Rami Doukky has written about Pyrazoles.
Rami Doukky
Connection Strength
9.302
Pyrazoles
  1. The prognostic value of regadenoson SPECT myocardial perfusion imaging: The largest cohort to date. J Nucl Cardiol. 2021 12; 28(6):2799-2807.
    View in: PubMed
    Score: 0.667
  2. Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm. J Nucl Cardiol. 2021 06; 28(3):967-977.
    View in: PubMed
    Score: 0.624
  3. Prognostic significance of ischemic electrocardiographic changes with regadenoson stress myocardial perfusion imaging. J Nucl Cardiol. 2020 10; 27(5):1521-1532.
    View in: PubMed
    Score: 0.592
  4. Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review. J Nucl Cardiol. 2018 02; 25(1):137-149.
    View in: PubMed
    Score: 0.547
  5. The significance of post-stress decrease in left ventricular ejection fraction in patients undergoing regadenoson stress gated SPECT myocardial perfusion imaging. J Nucl Cardiol. 2018 08; 25(4):1313-1323.
    View in: PubMed
    Score: 0.532
  6. Impact of integrating heart rate response with perfusion imaging on the prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol. 2017 10; 24(5):1666-1671.
    View in: PubMed
    Score: 0.508
  7. Impact of a regimented aminophylline administration protocol on the burden of regadenoson-induced ischemia detected by SPECT myocardial perfusion imaging. J Nucl Cardiol. 2017 10; 24(5):1571-1578.
    View in: PubMed
    Score: 0.507
  8. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol. 2017 02; 24(1):112-118.
    View in: PubMed
    Score: 0.489
  9. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease. J Nucl Cardiol. 2016 06; 23(3):560-9.
    View in: PubMed
    Score: 0.481
  10. The prognostic value of regadenoson stress: Has the case been made? J Nucl Cardiol. 2015 Aug; 22(4):608-10.
    View in: PubMed
    Score: 0.472
  11. Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging. J Nucl Cardiol. 2015 Aug; 22(4):700-13.
    View in: PubMed
    Score: 0.470
  12. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol. 2015 Oct; 22(5):1008-18.
    View in: PubMed
    Score: 0.458
  13. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial. J Nucl Cardiol. 2014 Jun; 21(3):496-502.
    View in: PubMed
    Score: 0.433
  14. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis. 2014; 9:129-37.
    View in: PubMed
    Score: 0.431
  15. Age and gender as predictors of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE trial. Am J Ther. 2013 Nov-Dec; 20(6):622-9.
    View in: PubMed
    Score: 0.424
  16. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol. 2013 Apr; 20(2):205-13.
    View in: PubMed
    Score: 0.399
  17. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial. Int J Cardiovasc Imaging. 2013 Jun; 29(5):1029-37.
    View in: PubMed
    Score: 0.399
  18. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial". J Nucl Cardiol. 2012 Jun; 19(3):448-57.
    View in: PubMed
    Score: 0.378
  19. The prognostic implications of ST-segment and T-wave abnormalities in patients undergoing regadenoson stress SPECT myocardial perfusion imaging. J Nucl Cardiol. 2022 04; 29(2):810-821.
    View in: PubMed
    Score: 0.172
  20. The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date. J Nucl Cardiol. 2022 Feb; 29(1):101-110.
    View in: PubMed
    Score: 0.169
  21. The significance of automatically measured transient ischemic dilation in identifying severe and extensive coronary artery disease in regadenoson, single-isotope technetium-99m myocardial perfusion SPECT. J Nucl Cardiol. 2015 Jun; 22(3):526-34.
    View in: PubMed
    Score: 0.117
  22. Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation. J Womens Health (Larchmt). 2017 03; 26(3):214-221.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.